Roivant Sciences Ltd. Common Shares
Here’s whether Roivant Sciences Ltd. Common Shares (ROIV) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+4.04% over 10 days); RSI 48 — healthy momentum range; strong 1-year return of +207.6%; 3-month momentum positive (+27.7%). Concerns: declining volume on rally — weak conviction (0.72x 30d avg). Currently 5.4% off its 52-week high. Score: +6/7.
ROIV is in a confirmed uptrend, trading above both its 50-day ($32.07) and 200-day ($25.98) moving averages. An RSI of 47.6 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +207.6% compares to +16.5% for SPY (beat the market by 191.2%).